Working… Menu

Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02872025
Recruitment Status : Recruiting
First Posted : August 18, 2016
Last Update Posted : January 29, 2021
Merck Sharp & Dohme Corp.
ModernaTX, Inc.
Information provided by (Responsible Party):
Laura Esserman, University of California, San Francisco

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : December 31, 2021